Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05136144
Other study ID # DBI-SM-201
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date October 19, 2021
Est. completion date July 31, 2024

Study information

Verified date September 2023
Source DermBiont, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a first-in-humans adaptive design open label trial to explore the safety and efficacy of SM-020. Multiple dosing cohorts will be enrolled. The first cohort will have a two-week treatment period of twice daily applications followed by a four-week follow-up period. Based on the results at any time from the first and subsequent cohorts, additional cohorts will explore different dosing regimens.


Description:

This is a first-in-humans adaptive design open label trial to explore the safety and efficacy of SM-020. Multiple dosing cohorts will be enrolled. The first cohort will have a two-week treatment period of twice daily applications followed by a four-week follow-up period. Based on the results at any time from the first and subsequent cohorts, additional cohorts will explore different dosing regimens. Variables to be considered in the design of cohorts include frequency of application and duration of application. The maximum duration of a treatment period is 12 weeks for any subject. 35 Subjects have been enrolled to date in the following 7 cohorts: Cohort 1: SM-020 gel 1.0% BID (Bis in die) for 14 days Cohort 2: SM-020 gel 1.0% BID for 28 days Cohort 3: SM-020 gel 1.0% BID pulsed dosing 4 days on/4 days off Cohort 4: SM-020 gel 1.0% BID for 28 days to facial SKs Cohort 5: SM-020 gel 1.0% TIW (Three times a week) under occlusion for 28 days Cohort 6: SM-020 gel 1.0% BID for 28 days with intertriginous SKs Cohort 7: SM-020 gel 0.1% BID for 28 days to facial SKs Anticipated subsequent cohorts to be enrolled: Cohort 8: SM-020 gel 1.0% BID for 56 days Cohort 9: SM-020 gel 1.0% BID for 28 days Cohort 10: SM-020 gel 1.0% QD (Quaque die) for 28 days Cohort 11: SM-020 gel 0.1% BID for 28 days


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 70
Est. completion date July 31, 2024
Est. primary completion date May 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Must be able to comprehend and willing to sign an informed consent form (ICF). 2. At least 18 years of age. 3. Must have a minimum of 5 eligible facial, truncal, intertriginous, or extremity SKTLs. A maximum of 10 will be targeted for treatment. There will be a maximum of 5 PLA 2's per subject. An eligible SKTL must each: 1. Have one or more of the following clinical features throughout the entirety of the lesion consistent with SKs: stuck-on, warty, waxy, scaly, milia-like cyst, tan to black 2. For subjects randomized for assessment with clinical diagnosis and dermoscopy, SKs must also have one or more of the dermoscopy features throughout the entirety of the lesion: moth-eaten border, fingerprinting structures, network-like pattern, network pattern, crypts (comedo-like openings), milia cysts, pinpoint vessels, hairpin vessels, fat fingers, sharp demarcation, blue-white pigmentation, more than one color, cerebriform structure, irregular, polymorphic pattern, fissures, white artefacts, irregular vessels (Simionescu et al., 2012). 3. Have a Physician's Lesion Assessment (PLA) of 2 (a thickness that is =1mm) or 3 (a thickness that is >1mm) 4. Have a greatest diameter that is =5mm and =15mm 5. Be a discrete, well-defined, separate lesion 6. Not be covered with hair which, in the Investigator's opinion, would interfere with the study gel treatment or the study evaluations 7. Not be pedunculated 8. Not be on the eyelid 9. Not be within 5mm of the orbital rim 4. Must be free of any known disease state or physical condition which, in the Investigator's opinion, might impair evaluation of any SKTL or which exposes the subject to an unacceptable risk by study participation. 5. Must be willing and able to follow all study instructions and to attend all study visits. 6. As applicable, technical ability and willingness to apply Investigational Product (IP). 7. Must be willing to have all partial, incompletely, or non-responding SKTLs removed surgically by shave excision during the final visit. Exclusion Criteria: 1. Positive urine pregnancy test, pregnant, lactating, or female of childbearing potential who does not agree to use an active method of birth control for the duration of the study. 2. SK lesions that are clinically atypical and/or rapidly growing in size. 3. Presence of multiple eruptive SK lesions (sign of Leser-Trelat). 4. Current systemic malignancy. 5. Any use of the following systemic therapies within the specified period, or unwilling to meet the following washouts, prior to the Baseline visit: 1. Retinoids; 180 days 2. Glucocorticosteroids; 28 days 3. Anti-metabolites (e.g., methotrexate); 28 days 6. Any use of the following topical therapies within the specified period, or unwilling to meet the following washouts, prior to the Baseline visit and while on study on, or in a proximity to any SKTL that, in the Investigator's opinion, could interfere with the investigational product study treatment applications or the study assessments: 1. Laser, light or other energy-based therapy [e.g., intense pulsed light (IPL), photo-dynamic therapy (PDT)]; 180 days 2. Liquid nitrogen, electrodesiccation, curettage, imiquimod, 5-fluorouracil, or ingenol mebutate; 60 days 3. Retinoids; 28 days 4. Microdermabrasion or superficial chemical peels; 14 days 5. Glucocorticosteroids or antibiotics; 14 days 7. Occurrence or presence of any of the following within the specified period prior to the Baseline visit on or in the proximity of any SKTL that, in the Investigator's opinion, could interfere with the investigational product study treatment applications or the study assessments: 1. Cutaneous malignancy; 180 days 2. Sunburn; currently 3. A pre-malignancy (e.g., actinic keratosis); currently 4. Body art (e.g., tattoos, piercing, etc.); currently 8. History of sensitivity to any of the ingredients in the investigational product. 9. Any current skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.), or other condition(s) (e.g., sunburn, excessive hair, open wounds, lupus, photosensitive disorders etc.) that, in the opinion of the Investigator, might put the subject at undue risk by study participation or interfere with the study conduct or evaluations. 10. Participation in an investigational drug trial in which administration of an investigational study medication occurred within 30 days prior to the Screening visit. 11. History of hypertrophic scarring or keloid formation.

Study Design


Intervention

Drug:
SM-020
Topical Akt Inhibitor SM-020 Gel

Locations

Country Name City State
El Salvador Zepeda Dermatologia Santa Tecla La Libertad

Sponsors (2)

Lead Sponsor Collaborator
DermBiont, Inc. Zepeda Dermatologia

Country where clinical trial is conducted

El Salvador, 

Outcome

Type Measure Description Time frame Safety issue
Primary Superiority of 56-day BID treatment with SM-020 gel 1.0% over 28-day BID treatment with SM-020 gel 1.0% Measured by the proportion of all SKTLs (Seborrheic Keratosis Target Lesion) that achieve clearance (PLA score of 0) at final study visit Through 20 weeks
Primary Superiority of 28-day BID treatment with SM-020 gel 1.0% over 28-day QD treatment with SM-020 gel 1.0% Measured by the proportion of all SKTLs that achieve clearance (PLA score of 0) Through 20 weeks
Primary Superiority of 28-day BID treatment with SM-020 gel 1.0% over 28-day BID treatment with SM-020 gel 0.1% Measured by the proportion of all SKTLs that achieve clearance (PLA score of 0) Through 20 weeks
Secondary Superiority of 56-day BID treatment with SM-020 gel 1.0% over 28-day BID treatment with SM-020 gel 1.0% Measured by the proportion of facial SKTLs, truncal SKTLs, intertriginous SKTLs, and extremity SKTLs that achieve clearance (PLA score of 0) Through 20 weeks
Secondary Superiority of 56-day BID treatment with SM-020 gel 1.0% over 28-day BID treatment with SM-020 gel 1.0% Measured by the proportion of all SKTLs, facial SKTLs, truncal SKTLs, intertriginous SKTLs, and extremity SKTLs with a PLA of 0 or 1 Through 20 weeks
Secondary Superiority of 56-day BID treatment with SM-020 gel 1.0% over 28-day BID treatment with SM-020 gel 1.0% Measured by the proportion of subjects achieving clearance of all SKTLs, facial SKTLs, truncal SKTLs, intertriginous SKTLs, and extremity SKTLs Through 20 weeks
Secondary Superiority of 56-day BID treatment with SM-020 gel 1.0% over 28-day BID treatment with SM-020 gel 1.0% Measured by the proportion of subjects achieving clearance of at least 5 of all SKTLs Through 20 weeks
Secondary Superiority of 56-day BID treatment with SM-020 gel 1.0% over 28-day BID treatment with SM-020 gel 1.0% Measured by the proportion of all SKTLs/subject, facial SKTLs/subject, truncal SKTLs/subject, intertriginous SKTLs/subject, and extremity SKTLs/subject achieving a PLA of 0 Through 20 weeks
Secondary Superiority of 56-day BID treatment with SM-020 gel 1.0% over 28-day BID treatment with SM-020 gel 1.0% Measured by the proportion of all SKTLs, facial SKTLs, truncal SKTLs, intertriginous SKTLs, and extremity SKTLs with a SSA (Subject's Self-Assessment) of 0 or 1 Through 20 weeks
Secondary Superiority of 56-day BID treatment with SM-020 gel 1.0% over 28-day BID treatment with SM-020 gel 1.0% Measured by the proportion of all SKTLs, facial SKTLs, truncal SKTLs, intertriginous SKTLs, and extremity SKTLs with a SSA of 0 Through 20 weeks
Secondary Superiority of 56-day BID treatment with SM-020 gel 1.0% over 28-day BID treatment with SM-020 gel 1.0% Measured by the percent recurrence of all SKTLs, facial SKTLs, truncal SKTLs, intertriginous SKTLs, and extremity SKTLs Through 20 weeks
See also
  Status Clinical Trial Phase
Completed NCT04229277 - Fast Track Diagnosis of Skin Cancer by Advanced Imaging N/A
Completed NCT02260180 - Study of A-101 for the Treatment of Seborrheic Keratosis Phase 2
Completed NCT01214564 - Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis Phase 2
Recruiting NCT06108024 - A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis Phase 2
Completed NCT06046144 - Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors
Completed NCT03846531 - Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Study N/A
Completed NCT03148691 - A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis Phase 2
Completed NCT03487588 - An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic Keratoses Phase 4
Completed NCT02160626 - Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis Phase 2
Completed NCT00540566 - Optical Biopsy of Human Skin in Conjunction With Laser Treatment
Completed NCT01159860 - Is Cryosurgery or Curettage More Effective at Treating Seborrheic Keratoses? N/A
Terminated NCT04688749 - Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
Completed NCT02667288 - An Open-Label Safety Study of A-101 Solution Phase 3
Completed NCT02667275 - A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis Phase 3
Completed NCT02667236 - A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis. Phase 3
Completed NCT05353374 - Effectiveness of Sodium Fusidate Ointment Compared to Petrolatum for Wound Healing Following Cauterization N/A
Terminated NCT04249115 - Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study N/A